Item 5.07 Submission of Matters to a Vote of Security Holders.
OnJune 8, 2021 ,NGM Biopharmaceuticals, Inc. (the "Company") held its 2021 annual meeting of stockholders (the "Annual Meeting"). The following is a brief description of each matter voted on at the Annual Meeting, as well as the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter can be found in the Company's definitive proxy statement filed with theU.S. Securities and Exchange Commission onApril 28, 2021 . 1. Election of Directors Director Name Votes For Votes Against Votes Withheld Broker Non-Votes Jin-Long Chen, Ph.D. 55,573,873 0 7,840,620 5,806,958 Roger M. Perlmutter, M.D., Ph.D. 63,369,234 0 45,259 5,806,958 The Class II director nominees were elected to hold office until the Company's 2024 annual meeting of stockholders and until their successors are duly elected and qualified. 2. Ratification of Selection of Independent Registered Public Accounting Firm Firm Votes For Votes Against Abstentions Broker Non-Votes Ernst & Young LLP 69,181,486 25,320 14,645 0
The Company's stockholders ratified the appointment of
--------------------------------------------------------------------------------
© Edgar Online, source